#United States #Board of Directors #BioLife Solutions #Bothell #Cathy Coste

BioLife Solutions Welcomes Cathy Coste to Its Leadership Team

BioLife Solutions, Inc. (Nasdaq: BLFS), a prominent name in the bioproduction sector, has announced the appointment of Cathy Coste to its board of directors. This strategic move not only increases the board's membership to seven but also signifies a commitment to enhancing corporate governance as the company progresses in the cell and gene therapy market.

A Suitable Addition

Coste brings over 40 years of extensive experience in financial oversight and corporate governance. She previously served as a senior partner at Deloitte, where she honed her expertise in audits, risk management, and compliance. Her tenure at Deloitte allowed her to work with more than two dozen life sciences firms, equipping her with the requisite skills to lead the audit committee at BioLife.

Roderick de Greef, Chairman and CEO of BioLife, expressed confidence in Coste’s abilities, stating, “Cathy is a highly qualified financial professional, making her ideal for our audit committee chair position.” He emphasized her impressive track record as both an executive and auditor in complex corporate environments.

Transition and Future Growth

The timing of Coste’s appointment is particularly poignant, as BioLife transitions into a dedicated enabler of cell and gene therapies. The company has recently completed significant steps toward market positioning for continued revenue growth and profitability. Ms. Coste herself commented, “This is an exciting and pivotal time to join the board at BioLife,” indicating her enthusiasm for the company’s future prospects.

Recognizing the advancements in the cell and gene therapy sphere, Coste’s insights will likely prove invaluable as BioLife seeks to navigate its evolving landscape. Her experience with financial strategy and oversight will play a critical role in aligning the company's financial integrity with its ambitious goals.

Previous Experience and Credentials

Before her role at BioLife, Coste made substantial contributions at Deloitte over a span of three decades. In addition to leading finance and internal audit teams globally, she participated in numerous audit committee meetings, showcasing her capabilities in governance and strategic oversight. Her earlier career includes responsibilities at Mervyn's, where she handled various accounting and operational roles.

Beyond her newest role with BioLife, Coste serves as a director and audit committee chair for several companies, including Biomerica, Inc. and Renalytix plc as well as Minerva Surgical, Inc., further underlining her prominence in health-related sectors.

Cathy Coste holds a Bachelor of Arts in Business Administration with an accounting focus from California State University, Hayward. Additionally, she completed the prestigious Corporate Director's Certificate Program at Harvard Business School, further solidifying her qualifications.

Conclusion

In conclusion, the appointment of Cathy Coste marks a significant chapter for BioLife Solutions as it embarks on a journey of strategic growth and transformation in the cell and gene therapy domain. With her extensive expertise backing the company's governance and financial integrity, stakeholders can anticipate a future marked by progress and innovation. As BioLife continues to lead in bioproduction tools and services, the integration of leaders like Coste will be key in achieving its long-term objectives. For more information about BioLife Solutions and their commitment to cell and gene therapies, visit BioLife Solutions.

For inquiries, contact Troy Wichterman, Chief Financial Officer at BioLife Solutions.